文献速递关节外科

低剂量普瑞巴林作为全膝关节置换术后疼痛控制现代多模式药物的镇痛疗效与副作用:一项前瞻性、双盲、随机对照试验

Analgesic Efficacy and Side Effects of Low-Dose Pregabalin As a Modern Multimodal Agent for Postoperative Pain Control After Total Knee Arthroplasty: A Prospective, Double-Blinded, Randomized Controlled Trial.
PubMed 文献 · J Arthroplasty · 2025-06-24

这项前瞻性双盲随机对照试验在全膝关节置换术后患者中比较普瑞巴林每日75 mg与推荐剂量150 mg连用14天的效果,发现两组视觉模拟量表疼痛评分至术后12周无统计学显著差异,但75 mg组头晕发生率更低且下地行走时间更快。作者据此提倡将75 mg普瑞巴林作为现代多模式镇痛方案的组成部分。

要点

  • 术后12周内各时间点,75 mg组与150 mg组视觉模拟量表评分无统计学显著差异。
  • 75 mg组头晕发生率17%,150 mg组61%(P < 0.001)。
  • 75 mg组下地行走时间27 ± 4小时,150 mg组30 ± 4小时(P < 0.001)。

核心结论

  • 全膝关节置换术后每日75 mg普瑞巴林连用14天的疼痛控制与150 mg相似,并具有下地行走更快和头晕减少的额外获益。
  • 作者提倡将75 mg普瑞巴林作为全膝关节置换术后现代多模式镇痛方案的组成部分,尤其在门诊全膝关节置换日益增多的趋势下。

研究设计与样本

  • 前瞻性、双盲、随机对照试验,纳入接受单侧初次全膝关节置换术的患者,比较术后每日普瑞巴林75 mg与150 mg连用14天的疗效。
  • 所有患者均接受术中糖皮质激素、脊髓麻醉、收肌管阻滞、关节囊周围注射及其他标准化用药。
  • 主要结局为术后24小时、48小时及2、6、12周静息和运动时的视觉模拟量表疼痛评分。
  • 次要结局包括吗啡用量、不良事件、下地行走时间、膝关节屈曲度、膝关节学会评分、两分钟步行试验和计时起立-行走试验。
  • 证据等级为治疗性I级。

主要发现

  • 术后至12周各时间点,75 mg组与150 mg组视觉模拟量表评分无统计学显著差异。
  • 75 mg组头晕发生率为17%,150 mg组为61%(P < 0.001)。
  • 75 mg组下地行走时间为27 ± 4小时,150 mg组为30 ± 4小时(P < 0.001)。
  • 其他结局指标在两组间无显著差异。

关键数值与推荐

  • 当前推荐剂量为术后每日150至300 mg连用14天,报告的不良反应包括头晕和镇静。
  • 本研究比较的剂量为术后每日普瑞巴林75 mg与150 mg,均连用14天。

临床怎么用

  • 作者提倡将75 mg普瑞巴林作为全膝关节置换术后现代多模式镇痛方案的组成部分,尤其在门诊全膝关节置换日益增多的趋势下。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregabalin is an essential component of contemporary multimodal analgesic strategies for managing postoperative pain after total knee arthroplasty (TKA). The current recommendation is a daily dosage of 150 to 300 mg for 14 days postoperatively. Reported side effects include dizziness and sedation. Our study aimed to investigate the analgesic efficacy and side effects of low-dose pregabalin (75 mg) compared with the recommended 150 mg dose. METHODS: We conducted a double-blinded, randomized controlled trial in patients undergoing unilateral primary TKA to compare the efficacy of postoperative pregabalin at 75 versus 150 mg daily for 14 days. All patients received intraoperative corticosteroids, spinal anesthesia, adductor canal block, pericapsular injection, and other standardized medications. The primary outcome was pain, assessed using the visual analog scale at rest and during motion at 24, 48 hours, and at two, six, and 12 weeks postoperatively. Secondary outcomes included morphine consumption, adverse events, time to ambulation, knee flexion, Knee Society Scores, the Two-Minute Walking Test, and the Timed Up-and-Go Test. RESULTS: Our results revealed no statistically significant difference in visual analog scale scores between the 75 and 150 mg groups at various time points up to 12 weeks postsurgery. However, the 75 mg group exhibited substantially lower incidences of dizziness (17 versus 61% in the 150 mg group, P < 0.001) and faster time to ambulation (27 ± four versus 30 ± four hours in the 150 mg group, P < 0.001). Other outcome measures showed no notable variances between the two groups. CONCLUSIONS: A 75 mg dosage of pregabalin for 14 days post-TKA provided pain control similar to 150 mg, with additional benefits of faster ambulation and reduced dizziness. Therefore, we advocate for the use of 75 mg pregabalin as part of a contemporary multimodal analgesic regimen for postoperative pain management after TKA, particularly in the growing trend of outpatient TKA. LEVEL OF EVIDENCE: Therapeutic level I.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Kukreja S, Pinitchanon P, Pinsornsak P, et al. Analgesic Efficacy and Side Effects of Low-Dose Pregabalin As a Modern Multimodal Agent for Postoperative Pain Control After Total Knee Arthroplasty: A Prospective, Double-Blinded, Randomized Controlled Trial. J Arthroplasty. 2025. PMID: 40570986. doi:10.1016/j.arth.2025.06.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。